HLA-B* 5701 Screening Adult and Adolescent ARV Guidelines.
Jan 10, 2011. The PREDICT-1 study randomized patients before starting ABC either to be. The specificity of the HLA-B*5701 test in predicting ABC HSR is lower than the sensitivity. HLA-B*5701 screening for hypersensitivity to abacavir. Aug 15, 2013. Abacavir HSR is a multi-organ syndrome characterized by 2 or more clinical. 2 studies that support the recommendation for pre-therapy screening for the. Data from PREDICT-1 estimates that 61% of HLA-B*5701 positive. A research brief on pretreatment screening for HLA-B*5701 to decrease risk of abacavir. The reported rate of hypersensitivity reaction HSR to abacavir is. PREDICT-1, a double-blind study, randomized more than 1,900 HIV-infected.
HLA-B*5701 Screening for Abacavir Hypersensitivity - HIV InSite
Feb 9, 2010. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of. with HIV-1 treated with abacavir present a hypersensitivity reaction HSR. the patient develop HSR were taken from the PREDICT-1 study and the. The first retrospective study linking HLA-B* to abacavir HSR risk was. screening in all abacavir-eligible patients. for predicting incidence of HSR.
Correlation with HLA-B*5701 - Oxford Journals - Oxford University.
December 2008 were prospectively screened for HLA-B*5701. HCP5 rs2395029. development of abacavir HSR.1,2 Studies such as PREDICT-1 have. A number of studies have been performed to investigate whether HLA-B*5701 screening is an effective and feasible procedure to reduce the incidence of.